Pain-treating TENS device company NeuroMetrix (NSDQ:NURO) has agreed to pay at least $4 million to settle a false advertising case brought by the Federal Trade Commission FTC. The commission said today that the Woburn, Mass.-based company also agreed to stop making deceptive claims that its Quell device treats pain throughout the body when placed below the […]
NeuroMetrix CEO cuts his salary to $1
Dr. Shai N. Gozani, CEO of pain-treating TENS device company NeuroMetrix (NSDQ:NURO), is cutting his annual salary to $1 from a previous $422,200 — accepting a stock option to purchase 100,000 shares instead. The 2020 executive compensation package, approved Dec. 29 by the company board’s compensation committee, also cuts salaries in return for stock options for […]
How NeuroMetrix seeks to better relieve pain with AI
NeuroMetrix plans to add artificial intelligence to the latest iteration of its Quell transcutaneous electrical nerve stimulation (TENS) device. AI will allow Quell 2.0 to tailor treatment to each individual user, according to the Waltham, Mass.–based based company. Launched in September 2018 Quell 2.0 is 50% smaller and 20% more powerful than the original Quell, […]
NeuroMetrix lands $4m milestone payment from GSK deal
NeuroMetrix (NSDQ:NURO) said this week that it reeled in a $3.8 million milestone payment from its collaboration with GlaxoSmithKline‘s (NYSE:GSK) consumer healthcare unit. The strategic deal between the two groups was first announced in January this year. According to the terms of the deal, GSK acquired exclusive ownership of NeuroMetrix’s Quell pain-relief device outside the U.S., in exchange for […]
Teardown: Inside the Neurometrix Quell TENS device
A TENS device for transcutaneous electrical nerve stimulation wraps around the upper calf much like a wristwatch wraps around the wrist. Here are some of its operational secrets. By Lee Teschler A medical device called a Quell performs what’s called transcutaneous electrical nerve stimulation on the lower leg. This technique is said to relieve diabetic pain. None […]
NeuroMetrix inks Quell ownership deal with GlaxoSmithKline, posts Q1 earnings
NeuroMetrix (NSDQ:NURO) today saw shares fall despite announcing an exclusive deal giving GlaxoSmithKline (NYSE:GSK) ownership of its Quell technology for commercialization outside the US and releasing Street-beating first quarter earnings. In its deal with GlaxoSmithKline, Waltham, Mass.-based NeuroMetrix said it will receive payments totaling $26.5 million, with $5 million paid at closing and up to $21.5 million […]
NeuroMetrix touts Quell user-response study data
NeuroMetrix (NSDQ:NURO) yesterday released results from a clinical study of its Quell wearable device, touting its ability to treat chronic pain. Results from the trial were published in the Journal of Pain Research, the Waltham, Mass.-based company said. In the retrospective study, researchers examined data from 713 subjects using its Quell device to treat chronic pain […]
NeuroMetrix shares down on 2017 earnings miss
NeuroMetrix (NSDQ:NURO) saw shares dip today after it released 2017 earnings that missed analyst’s expectations, despite posting fourth quarter earnings that beat consensus. For the three months ended Dec. 31, the Waltham, Mass.-based company posted losses of $2.9 million on sales of $4.9 million, seeing its losses grow 2.3% while sales grew 32.7% compared with the […]
NeuroMetrix, GSK ink development deal for Quell wearable pain-relief tech
Shares in NeuroMetrix (NSDQ:NURO) soared this morning after the company announced it would partner with GlaxoSmithKline (NYSE:GSK) to expand development of NeuroMetrix’s Quell wearable pain-relief device. According to the terms of the deal, GSK’s consumer healthcare business will have exclusive rights to the Quell system for markets outside of the U.S., while NeuroMetrix will retain ownership of the device […]
NeuroMetrix closes $4m private placement
NeuroMetrix (NSDQ:NURO) said today it closed a $3.5 private placement round of Series F convertible preferred stock with funds slated to support continued commercialization of its Quell device. The Waltham, Mass.-based ocmpany floated a total of 3,500 Series F convertable shares at $1,000 per share. Shares sold in the round are convertible into 1.3 million shares […]
Is there a digital health solution for treating pain?
Could TENS devices be a potential answer to the opioid crisis? If they are, it’ll be thanks to digital health. Case in point is NeuroMetrix’s Quell device. Transcutaneous electrical nerve stimulation (TENS) gizmos have been around for decades. But they’ve had a reputation for being unwieldy, with a bunch of wires and pads. “TENS devices have been around […]
- 1
- 2
- 3
- …
- 9
- Next Page »
